1/15
10:00 am
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/13
03:49 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/8
09:06 am
vnda
Vanda Pharmaceuticals Says FDA Rejects Hetlioz as Jet Lag Treatment [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals Says FDA Rejects Hetlioz as Jet Lag Treatment [Yahoo! Finance]
1/8
07:00 am
vnda
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
Low
Report
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
1/6
08:27 am
vnda
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness [Yahoo! Finance]
Low
Report
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness [Yahoo! Finance]
1/5
07:17 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/5
07:17 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/3
01:08 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at
Wall Str
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at
Wall Str
1/2
01:29 pm
vnda
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn't (Rating Downgrade) [Seeking Alpha]
Low
Report
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn't (Rating Downgrade) [Seeking Alpha]
1/1
08:30 am
vnda
Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley [Yahoo! Finance]
Medium
Report
Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley [Yahoo! Finance]
1/1
07:41 am
vnda
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus [Seeking Alpha]
Medium
Report
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus [Seeking Alpha]
12/31
09:12 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at B. Riley.
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at B. Riley.
12/31
06:01 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "hold" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "hold" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/31
05:16 am
vnda
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin [Seeking Alpha]
Medium
Report
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin [Seeking Alpha]
12/30
07:42 pm
vnda
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness [Yahoo! Finance]
Medium
Report
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness [Yahoo! Finance]
12/30
06:13 pm
vnda
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
High
Report
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
12/17
01:07 pm
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
12/15
07:05 am
vnda
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis [Yahoo! Finance]
Medium
Report
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis [Yahoo! Finance]
12/15
07:00 am
vnda
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Low
Report
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
12/11
05:02 pm
vnda
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
Medium
Report
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
12/4
04:50 pm
vnda
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness [Yahoo! Finance]
Medium
Report
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness [Yahoo! Finance]
12/4
04:21 pm
vnda
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
Low
Report
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
12/1
07:20 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/29
12:31 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at
Wall S
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at
Wall S
11/28
07:34 am
vnda
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness [Yahoo! Finance]